Figures & data
Table 1. Clinical and demographic data for all patients with primary DAA failure.
Figure 1. Flow chart displaying the delay as well as death and drop-out rates during treatment and delay periods before and between salvage therapies for 288 patients with primary DAA failure.
![Figure 1. Flow chart displaying the delay as well as death and drop-out rates during treatment and delay periods before and between salvage therapies for 288 patients with primary DAA failure.](/cms/asset/79fd2e45-87d7-45ce-b6ca-34863aeccde8/infd_a_2244069_f0001_b.jpg)
Figure 2. Type of treatment given as first (A) and second (B) salvage treatment. ELV: elbasvir; GP: Glecaprevir/Pibrentasvir; GZP: grazoprevir; LDV: lepipasvir; R: ribavirin; SIM: simeprevir; SOF: sofosbuvir; VEL: velpatasvir; VOX: voxilaprevir.
![Figure 2. Type of treatment given as first (A) and second (B) salvage treatment. ELV: elbasvir; GP: Glecaprevir/Pibrentasvir; GZP: grazoprevir; LDV: lepipasvir; R: ribavirin; SIM: simeprevir; SOF: sofosbuvir; VEL: velpatasvir; VOX: voxilaprevir.](/cms/asset/04365ef7-906a-4f0c-89fe-d4ee0ebe1c4e/infd_a_2244069_f0002_b.jpg)
Table 2. Outcome of first and second salvage treatments according to presence of baseline cirrhosis.
Figure 3. (A) Overall survival (days) following primary DAA failure in 55 patients with and 85 patients without baseline cirrhosis. (B) Event-free survival (days) following primary DAA failure in 55 patients with and 85 patients without baseline cirrhosis. Events were defined as either death, liver decompensation or HCC. (C) Overall survival (days) following primary DAA failure in 117 patients with and 13 patients without SVR after first salvage treatment. (D) Event-free survival (days) following primary DAA failure in 117 patients with and 13 patients without SVR after first salvage treatment. Events were defined as death, liver decompensation or HCC. * Log rank test.
![Figure 3. (A) Overall survival (days) following primary DAA failure in 55 patients with and 85 patients without baseline cirrhosis. (B) Event-free survival (days) following primary DAA failure in 55 patients with and 85 patients without baseline cirrhosis. Events were defined as either death, liver decompensation or HCC. (C) Overall survival (days) following primary DAA failure in 117 patients with and 13 patients without SVR after first salvage treatment. (D) Event-free survival (days) following primary DAA failure in 117 patients with and 13 patients without SVR after first salvage treatment. Events were defined as death, liver decompensation or HCC. * Log rank test.](/cms/asset/4705ff20-0b45-479e-84ca-f79a949289dd/infd_a_2244069_f0003_c.jpg)